<DOC>
	<DOCNO>NCT00426127</DOCNO>
	<brief_summary>The purpose study assess effect treatment combination commercially available chemotherapy drug , docetaxel liposomal doxorubicin , blood thinner Enoxaparin pancreatic cancer . The main goal study find combination chemotherapy enoxaparin increase number individual whose tumor shrink .</brief_summary>
	<brief_title>Docetaxel Liposomal Doxorubicin Chemotherapy With Enoxaparin Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>The objective study determine safety efficacy combination docetaxel liposomal doxorubicin chemotherapy combine enoxaparin patient advance pancreatic cancer . Docetaxel ( TAXOTERE ) belong group anticancer drug call mitotic inhibitor . Liposomal doxorubicin ( Doxil ) anthracycline , think prevent nucleic acid synthesis need make DNA . Enoxaparin ( Lovenox ) anticoagulant . We interested combine chemotherapy blood thinner enoxaparin scientific link blood clot malignancy . This research do improve currently available chemotherapy treatment advance pancreatic cancer . The main goal study find combination chemotherapy enoxaparin increase number individual whose tumor shrink . Another purpose study find study treatment effect blood clotting level individual . We also determine incidence elevate D-dimer effect regimen level D-dimer , collect safety data regimen .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histologicallyconfirmed pancreatic carcinoma , least one lesion measurable CT scan long diameter &gt; 10mm , ( bone ) either previously irradiate , previously irradiate , demonstrate progression since radiation therapy base RECIST criterion . Locallyadvanced unresectable disease ineligible neoadjuvant therapy ( Stage III disease , unresectable medically unfit neoadjuvant treatment decline chemo radiation treatment ) metastatic disease . 18 year age great . Female patient childbearing potential must negative pregnancy test screening . All patient reproductive potential must agree practice effective contraception order participate study duration treatment 3 month post . WBC &gt; 3000 cells/mm3 segment 1800 , hemoglobin &gt; 10 g/dl , platelet &gt; 150,000 cells/mm3 , creatinine &lt; 1.5 mg/dl . Hepatic function : Total Bilirubin &lt; /= ULN . AST ALT Alkaline Phosphatase must within range allow eligibility . In determine eligibility abnormal two value ( AST ALT ) use . ECOG performance status &lt; /= 2 expect survival least 3 month . Stable neurological status without clinical evidence CNS metastases and/or stroke . Peripheral neuropathy must &lt; /= Grade 1 . Chemotherapy radiation therapy within precede 4 week . Patients must never docetaxel liposomal regular doxorubicin . Spinal/epidural anesthesia and/or catheter pain management New York Heart Association ( NYHA ) class III IV congestive heart failure Evidence duodenal erosion cancer . Heparin coumadin time enrollment , exception low dose coumadin ( 1 mg/day less ) administer prophylactically and/or heparin maintenance indwell line port . Acute DVT PE initial evaluation History severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 Pregnant breast feed Undergone major surgical procedure , open biopsy , major traumatic injury le 4 week prior study entry . Fine needle aspiration venous access device allow place &gt; 7 day study treatment begin . Presence active suspect acute chronic uncontrolled infection , include abscess fistula HIV positive History another malignancy within 5 year prior study entry , except curatively treat basal cell skin cancer cervical cancer situ Medical psychiatric illness would preclude study informed consent and/or history noncompliance medical regimen inability unwillingness return schedule visit Enoxaparin contraindicate patient active major bleed high risk bleeding , patient thrombocytopenia associate positive vitro test antiplatelet antibody presence enoxaparin sodium , patient hypersensitivity enoxaparin sodium . Patients know hypersensitivity heparin pork product treat enoxaparin injection constituent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Pancreatic</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Enoxaparin</keyword>
</DOC>